-
Baricitinib, sold
under the
brand name
Olumiant among others, is an
immunomodulatory medication used for the
treatment of
rheumatoid arthritis, alopecia...
- (tafasitamab-cxix),
Opzelura (Ruxolitinib),
Tabrecta (capmatinib),
Olumiant (
Baricitinib), and
Iclusig (ponatinib). In 2013,
Novartis acquired Incyte's c-Met...
- FDA
issued an
emergency use
authorization (EUA) for the
combination of
baricitinib with remdesivir, for the
treatment of
suspected or
laboratory confirmed...
- In June 2022, the U.S. Food and Drug
Administration (FDA)
authorized baricitinib, a J****
kinase (JAK) inhibitor, for the
treatment of
severe alopecia...
-
Administration (FDA)
requires a
boxed warning for the JAK
inhibitors tofacitinib,
baricitinib, and
upadacitinib to warn
about the
risks of
serious heart-related events...
-
relative effectiveness of
deuruxolitinib and
another J****
kinase inhibitor—
baricitinib—for
alopecia areata may vary
depending on the po****tion studied, both...
- crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib,
baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib...
- need
systemic medicines such as cyclosporin, methotrexate,
dupilumab or
baricitinib.
Other names of the
condition include "infantile eczema", "flexural eczema"...
-
alopecia spironolactone and flutamide. In June 2022, the FDA
authorized baricitinib for the
treatment of
severe alopecia areata. Minoxidil,
applied topically...
-
Later that month, the WHO
recommended the
rheumatoid arthritis drug
Baricitinib for
severe or
critical patients. It also
recommended the
monoclonal antibody...
